In its third-quarter results update this week, Novo Nordisk also revealed it has now filed for approval of oral semaglutide in the EU for launch in "selected markets," and sees the drug as "a big step forward in terms of expanding the market and for those individuals that align better with taking a pill for their obesity." Both companies have been investing heavily in direct-to-consumer (DTC) sales channels for cash purchasing of their current injectable products, and Novo Nordisk said on the call it will make oral semaglutide available across all its sales channels if approved.
[PMID: 3068032] PubMed record related to this compound for laboratory literature review
Because the skin is highly sensitive to internal imbalance, restoring antioxidant levels often leads to visible improvement in complexion and texture
HyperCharge is Hope
Fiber, protein, green tea extract, berberine, these can modestly influence satiety or blood sugar
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. Eventide: Biomedicine & Pharmacotherapy (2018)
